

Nephrology Division Newsletter

May – June 2014



Announcements

- ❖ **Kirsten Johansen, MD** was invited to give talk on “Associations between body composition and physical activity and function” at the XVII International Congress on Nutrition and Metabolism in Renal Disease 2014 held in Würzburg, Germany May 6-10, 2014 (<http://www.nephrology.dk/ICRNM.pdf>)
- ❖ **Dr. Sam James** at SFGH has become the site PI for “Study Of Diabetic Nephropathy With Atrasentan (SONAR)” a phase 3 randomized trial sponsored by AbbVie targeting to enrolling 4148 patients to evaluate the effect of atrasentan on time to doubling of serum creatinine or ESRD (<http://www.clinicaltrials.gov/ct2/show/NCT01858532>).
- ❖ **Dr. Meyeon Park** at Parnassus has become the site PI for “Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE).” The goal of this phase 3 trial sponsored by Janssen (targeted N = 3627) is to assess whether canagliflozin has a renal and vascular protective effect (<http://www.clinicaltrials.gov/ct2/show/NCT02065791>).
- ❖ **Steve Tomlanovich, MD** is featured in the Spring 2014 issue of the Department of Medicine Frontiers of Medicine in a piece titled “Broadening the circle of care.” http://medicine.ucsf.edu/images/fom/fom_spring2014.pdf



Fellowship Program

- ❖ **Dr. Vasanthan Jotwani's** F32 DK103451-01 titled “Novel biomarkers of kidney injury in HIV-infected men” has been approved for 2 years of funding.



Accomplishments and Awards

- ❖ **Kathleen Liu, MD, PhD** is contact PI for the recently funded R01DK101507 “Identifying opportunities to lower rates of AKI and improve outcomes.” The other PI's in this MPI grant are Drs. Chi-yuan Hsu and Alan Go.
- ❖ **The Nephrology Section at the SFVAMC** was recently rated as the most productive Nephrology Section of all VA Medical Centers in the United States and was ranked at the 95th percentile overall.